CAR T-cell therapy advances


Chimeric Antigen Receptor (CAR) T-cells are patient T-cells that have been engineered ex vivo to recognize tumor-specific antigens. They are revolutionizing therapy for certain blood cancers, but solid tumors are a difficult challenge. Here's one approach that seems to work on subcutaneous human medulloblastoma (MED8A) solid tumors in a mouse model. The CAR T-cells are injected in a hydrogel at the tumor site, which delivers them locally rather than the usual route, which is an IV drip. Of course, we've cured cancer in mice thousands of times, so hold your applause for now. https://www.technologynetworks.com/biopharma/news/car-t-cell-therapy-hydrogel-cures-cancer-in-mouse-models-360438?utm_source=facebook&utm_medium=social&utm_campaign=IFLS%20Referral&fbclid=IwAR2ktIBDV1UMDxjrW4m4Th_LfHhvXFo3bxinEx1mzIzIokyNsBBqlslwsOE

Comments

Popular posts from this blog

Two sides

Who chooses?

Black Earth